Quilter Plc Purchases 50 Shares of Amgen Inc. (NASDAQ:AMGN)

Quilter Plc increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,749 shares of the medical research company’s stock after acquiring an additional 50 shares during the period. Quilter Plc’s holdings in Amgen were worth $1,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. United Community Bank acquired a new position in shares of Amgen during the fourth quarter worth $29,000. Horizon Financial Services LLC acquired a new position in Amgen during the 1st quarter worth about $28,000. nVerses Capital LLC bought a new stake in shares of Amgen in the 2nd quarter valued at about $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the second quarter valued at about $33,000. Finally, Western Pacific Wealth Management LP bought a new position in shares of Amgen during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. TD Cowen boosted their target price on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Morgan Stanley cut their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 11th. Finally, Bank of America lifted their price objective on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Stock Performance

AMGN opened at $332.45 on Monday. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a market cap of $178.64 billion, a price-to-earnings ratio of 47.49, a PEG ratio of 2.93 and a beta of 0.61. The company’s fifty day moving average price is $328.18 and its two-hundred day moving average price is $304.00. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the previous year, the firm earned $5.00 earnings per share. The company’s revenue was up 20.1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.71%. Amgen’s dividend payout ratio is presently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.